SVCM
IKT icon

Saturn V Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Saturn V Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.49M Buy
3,863,445
+6,646
+0.2% +$11.8K 1.18% 18
2025
Q4 		$7.91M Buy
+3,856,799
New +$6.14M 1.45% 17

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Saturn V Capital Management's IKT Position: Q1 2026 in Review

Saturn V Capital Management increased its Inhibikase Therapeutics (IKT) stake by 0.17% in Q1 2026, buying an estimated $11.8K and bringing the position to 3,863,445 shares worth $6.49M. The position accounts for 1.18% of the portfolio, ranked #18.

Saturn V Capital Management first reported a position in IKT in Q4 2025 and has held it in 2 quarters since. The position peaked at $7.91M in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Saturn V Capital Management held 3,863,445 shares of Inhibikase Therapeutics worth $6.49M as of Q1 2026.
  • Saturn V Capital Management bought 6,646 Inhibikase Therapeutics shares in Q1 2026, an estimated $11.8K.
  • Inhibikase Therapeutics made up 1.18% of Saturn V Capital Management's portfolio in Q1 2026, its #18 holding.
  • Saturn V Capital Management first reported a position in Inhibikase Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Saturn V Capital Management's Inhibikase Therapeutics position peaked at $7.91M in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Saturn V Capital Management's 13F filing for Q1 2026, filed 15 May 2026.